The stock of Rocket Pharmaceuticals Inc (RCKT) has seen a -55.48% decrease in the past week, with a -64.49% drop in the past month, and a -68.25% decrease in the past quarter. The volatility ratio for the week is 50.96%, and the volatility levels for the past 30 days are at 23.04% for RCKT. The simple moving average for the last 20 days is -50.70% for RCKT’s stock, with a simple moving average of -77.19% for the last 200 days.
Is It Worth Investing in Rocket Pharmaceuticals Inc (NASDAQ: RCKT) Right Now?
The 36-month beta value for RCKT is at 0.68. Analysts have varying views on the stock, with 12 analysts rating it as a “buy,” 5 rating it as “overweight,” 6 as “hold,” and 0 as “sell.”
The public float for RCKT is 99.77M, and currently, shorts hold a 13.98% of that float. The average trading volume for RCKT on June 02, 2025 was 4.24M shares.
RCKT) stock’s latest price update
Rocket Pharmaceuticals Inc (NASDAQ: RCKT)’s stock price has soared by 11.20 in relation to previous closing price of 2.51. Nevertheless, the company has seen a loss of -55.48% in its stock price over the last five trading days. accessnewswire.com reported 2025-06-02 that NEW YORK, NY / ACCESS Newswire / June 2, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Rocket Pharmaceuticals, Inc. (“Rocket Pharmaceuticals, Inc.”) (NASDAQ:RCKT) concerning possible violations of federal securities laws. Rocket issued a press release on May 27, 2025, “announc[ing] an update related to RP-A501, its investigational gene therapy for Danon disease.
Analysts’ Opinion of RCKT
Many brokerage firms have already submitted their reports for RCKT stocks, with Evercore ISI repeating the rating for RCKT by listing it as a “In-line.” The predicted price for RCKT in the upcoming period, according to Evercore ISI is $5 based on the research report published on May 30, 2025 of the current year 2025.
Morgan Stanley, on the other hand, stated in their research note that they expect to see RCKT reach a price target of $7. The rating they have provided for RCKT stocks is “Equal-Weight” according to the report published on May 28th, 2025.
Leerink Partners gave a rating of “Market Perform” to RCKT, setting the target price at $8 in the report published on May 28th of the current year.
RCKT Trading at -55.78% from the 50-Day Moving Average
After a stumble in the market that brought RCKT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -89.65% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RCKT starting from Militello John, who sale 357 shares at the price of $6.45 back on May 20 ’25. After this action, Militello John now owns 64,027 shares of Rocket Pharmaceuticals Inc, valued at $2,301 using the latest closing price.
Schwartz Jonathan David, the insider of Rocket Pharmaceuticals Inc, sale 801 shares at $6.45 during a trade that took place back on May 20 ’25, which means that Schwartz Jonathan David is holding 235,255 shares at $5,163 based on the most recent closing price.
Stock Fundamentals for RCKT
The total capital return value is set at -0.62. Equity return is now at value -60.45, with -53.17 for asset returns.
Based on Rocket Pharmaceuticals Inc (RCKT), the company’s capital structure generated 0.06 points at debt to capital in total, while cash flow to debt ratio is standing at -8.23. The debt to equity ratio resting at 0.06. The interest coverage ratio of the stock is -143.2.
Currently, EBITDA for the company is -273.2 million with net debt to EBITDA at 0.1. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.19.
Conclusion
In conclusion, Rocket Pharmaceuticals Inc (RCKT) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
